Iranian national thalassaemia screening programme

British Medical Journal

Volumn 329, Issue 7475, 2004, Pages 1134-1137

  Samavat, Ashraf ^a   Modell, Bernadette ^b  

^a MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

BETA THALASSEMIA; DEVELOPING COUNTRY; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE FINANCING; HEALTH EDUCATION; HEALTH INSURANCE; HEALTH PROGRAM; HETEROZYGOTE; HUMAN; IRAN; LABORATORY DIAGNOSIS; MARRIAGE; MICROCYTOSIS; PRENATAL DIAGNOSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

EID: 8744272457     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7475.1134     Document Type: Review

References (19)

1. Alwan A, Modell B. Recommendations for introducing genetics services into developing countries. Nature Rev Genetics 2003;4:61-8.
2. Farhud D, Sadighi H. Investigation of prevalence of thalassaemia in Iran. Iran J Public Health 1997;26:1-2.
3. Shadpour K. The PHC experience in Iran. Teheran: Unicef, 1994.
4. Cao A, Rosatelli. Screening and prenatal diagnosis of the haemoglobinopathies. Balliere's Clin Haematol 1993;6:263-86.
5. Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet 1981;i:369-70.
6. Loukopoulos D. Current status of thalassaemia and the sickle cell syndromes in Greece. Semin Hematol 1996;33:76-86.
7. Maggio A, Caronia F, Orlandi F. Prenatal diagnosis of haemoglobinopathies in Sicily. Lancet 1992;339:1361-2.
8. Modell B, Ward RHT, Fairweather DVI. Effect of introducing antenatal diagnosis on the reproductive behaviour of families at risk for thalassaemia major. BMJ 1980;ii:737.
9. Alwan AA, Modell B. Community control of genetic and congenital disorders. Cairo: World Health Organisation Regional Office for the Eastern Mediterranean, 1997. (EMRO Technical Publications Series 24.)
10. Report of a WHO meeting on ethical issues in medical genetics. Proposed international guidelines on ethical issues in medical genetics and genetics services. http://www.who.int/genomics/publications/en/ethicalguidelines1998.pdf (accessed 1 Nov 2004).
11. General Haematology Task Force of the British Committee for Standards in Haematology. The laboratory diagnosis of haemoglobinopathies. Br J Haematol 1998;101:783-92.
12. Modell B, Darlison M, Khan M, Harris R. Role of genetic diagnosis registers in ongoing consultation with the community. Comm Gen 2000;3:144-7.
13. Modell B, Khan M, Darlison M, King A, Layton M, Old J, et al. Use of a national diagnosis register for surveillance of an inherited disorder: the example of beta thalassaemia in the United Kingdom. Bull World Health Organ 2001;79:1006-13.
14. Modell B, Harris R, Lane B, Khan M, Darlison M, Petrou M, et al. Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential enquiry. BMJ 2000;320:325-90.
15. Gohari LH, Petrou M, Felekis X, Christopoulos G, Kleanthous M. Identification of alpha-thalassemia mutations in Iranian individuals with abnormal hematological indices and normal Hb A2. Hemoglobin 2003;27:129-32.
16. th meeting of the American Society for Human Genetics, Baltimore, USA, 1997. Am J Hum Genet 1997;61(suppl):abstract No 829.
17. Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, et al. The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001;25:285-96.
18. Angastiniotis MA, Kyriakidou S, Hadjiminas M. How thalassaemia was controlled in Cyprus. World Health Forum 1986;7:291-7.
19. Ahmed S, Saleem M, Modell B, Petrou M. Screening extended families for genetic haemoglobin disorders in Pakistan. N Engl J Med 2001;347:1162-8.